Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Leukemia
|
July 28, 2025
Rare germline variant in NFATC4 associated with familial CLL
Gilad Itchaki, Harrison Bai, Grace Tiao, et al.
Endoscopy International Open
|
October 20, 2022
Second exam of right colon improves adenoma detection rate: Systematic review and meta-analysis of randomized controlled trials
Faisal Kamal, Muhammad Ali Khan, Wade Lee-Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic Leukemia
Benjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Heliyon
|
January 14, 2022
DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial
Judith C Hugh, Lacey S J Haddon, John Maringa Githaka, et al.
Blood Cancer Journal
|
February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
Clinical and Translational Gastroenterology
|
December 22, 2023
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans H Herfarth, Anita Afzali, Monika Fischer, et al.
Blood
|
September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations
John R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Inflammatory Bowel Diseases
|
June 14, 2022
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Millie D Long, Anita Afzali, Monika Fischer, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Leukemia
|
November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia
Deepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Leukemia
|
July 28, 2025
Rare germline variant in NFATC4 associated with familial CLL
Gilad Itchaki, Harrison Bai, Grace Tiao, et al.
Endoscopy International Open
|
October 20, 2022
Second exam of right colon improves adenoma detection rate: Systematic review and meta-analysis of randomized controlled trials
Faisal Kamal, Muhammad Ali Khan, Wade Lee-Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic Leukemia
Benjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Heliyon
|
January 14, 2022
DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial
Judith C Hugh, Lacey S J Haddon, John Maringa Githaka, et al.
Blood Cancer Journal
|
February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
Clinical and Translational Gastroenterology
|
December 22, 2023
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans H Herfarth, Anita Afzali, Monika Fischer, et al.
Blood
|
September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations
John R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Inflammatory Bowel Diseases
|
June 14, 2022
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Millie D Long, Anita Afzali, Monika Fischer, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Leukemia
|
November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia
Deepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Page
of 10